Country’s clinical trials business will be more than tripple to about US$ 546 million by 2010, capturing 15 per cent of the global market, according to industry body Assocham. At present, country’s clinical trials industry is valued at about US$ 150 mn. The US$ 10-bn global clinical trials industry has a large potential growth for future since global revenues have increased by 12-14 per cent in last few years, the chamber said. In future, this growth would exceed 20 per cent from 2010 onwards, it said. Between 1996 to 2000, the US outsourced 4,230 clinical trials, of which only one came to India whereas during 2001 to 2005, USA outsourced 12,022 trials of which India bagged 192 orders, Assocham President Sajjan Jindal said while releasing the report on ‘Domestic Clinical Trials Business’. As of 2006 and 2007, there were over 1,500 sites that conducted clinical trials. Out of these, about 300 were registered with FDA (Food Drugs Administration of the US). That shows how the business of clinical trials and its outsourcing is growing. It also shows the lead India has taken and what it is poised for the future, he said. As India’s population is about 1.1 billion and thereby it makes it possible to undertake trials recruiting large number of subjects. Faster patient enrolment is essential to complete the clinical trial processed fast, Assocham said. The other advantages of India are that it has the second largest pool of qualified doctors, about six lakh qualified practicing physicians and over 171 medical colleges, it added.